STADA fixes subscription price for first tranche of capital increase at EUR 37.50
09/26/2003 . Press Release
The executive board of STADA Arzneimittel AG today determines the subscription price, with the approval of the supervisory board, for the new shares of the first tranche of the capital increase, which the shareholders will be offered to subscribe for, at EUR 37.50 per share. Deutsche Bank, the Global Coordinator, as well as DZ Bank, Deutsche Apotheker- und Ärztebank and HSBC Trinkaus & Burkhardt have underwritten 5,000,000 new shares together with the obligation to offer these shares for subscription at that price, with the exception of 1,712 new fractional shares to STADA shareholders at a ratio of 4:1. According to the subscription ratio, one new STADA share may be subscribed for four old STADA shares for a subscription price of EUR 37.50.
The proceeds of the subscription rights offering are expected to be approximately EUR 187 million. The subscription period is expected to commence on 30 September 2003 and end on 13 October 2003. During the period from 23 September 2003 until 9 October 2003, it is expected that the relevant subscription rights may also be traded on the official market of the Frankfurt Stock Exchange.
“The subscription price determined by us provides our shareholders with an attractive opportunity to continue to be part of the STADA success story. We expect that many of our shareholders will avail themselves of this opportunity”, stated Wolfgang Jeblonksi, CFO of STADA Arzneimittel AG.
As announced on 22 September 2003, STADA intends, in addition to this first tranche, to implement a second tranche of the capital increase, which will exclude subscription rights. The date and details of the capital increase in the second tranche will be provided at short notice after expiry of the subscription period depending on the current market situation. A total value of approximately EUR 250 million to 350 million is projected for both tranches of the capital increase.
“The influx of funds from this capital increase will enable STADA to continue its existing growth strategy through organic growth but also through the acquisition of products as well as through selective acquisitions in selected markets. In that respect, STADA will, naturally, continue to pursue its proven acquisition strategy, that means that it will only purchase acquisition targets which are in line with the structure and size of the group”, explained Hartmut Retzlaff, chairman of the executive board of STADA.
For more information, please contact:
STADA Arzneimittel AG
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506